**Financial Highlights:** Orchid Pharma's Q1 FY26 financials show a notable decline.

Sales were down 29% YoY to 173 Cr.

EBITDA dropped 27% to 30 Cr, with PBT and PAT each falling 38% to 18 Cr.

Despite the sales decrease, EBITDA margin held steady at 17%, and Gross Margin improved to 43% from 39%. For the full FY25, sales grew 13% and PAT increased 12%. **Strategic Initiatives & Growth Drivers:** The presentation did not detail any strategic initiatives, new launches, or expansion plans. **Business Developments:** No information on recent acquisitions, partnerships, or product rollouts was provided. **Market Position & Competitive Advantage:** The document offered no commentary on the company's market position, differentiation, or competitive advantages. **Investor Implications:** The significant Q1 FY26 downturn in revenue and profit marks a challenging start to the fiscal year, contrasting with FY25's growth.

Investors should monitor future quarters for recovery, indicating potential execution risk.